MEMORANDUM FOR: Science Writers and Editors on the Journal Press List: 20-Year Follow-up Shows No Mortality Reduction in a Lung Cancer Screening Trial

2000 ◽  
Vol 92 (16) ◽  
pp. 1279-1279
Author(s):  
K. Arnold ◽  
D. Eckstein
Keyword(s):  
Lung Cancer ◽  
Cancer Screening ◽  
Lung Cancer Screening ◽  
Mortality Reduction ◽  
Cancer Screening Trial ◽  
Screening Trial

scholarly journals Effect of CT screening on smoking habits at 1-year follow-up in the Danish Lung Cancer Screening Trial (DLCST)

Thorax ◽  
2008 ◽  
Vol 64 (5) ◽  
pp. 388-392 ◽  
Author(s):  
H Ashraf ◽  
P Tonnesen ◽  
J Holst Pedersen ◽  
A Dirksen ◽  
H Thorsen ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Screening ◽  
Lung Cancer Screening ◽  
Smoking Habits ◽  
Ct Screening ◽  
Cancer Screening Trial ◽  
Screening Trial

scholarly journals Lung cancer screening and smoking abstinence: 2 year follow-up data from the Dutch-Belgian randomised controlled lung cancer screening trial

Thorax ◽  
2010 ◽  
Vol 65 (7) ◽  
pp. 600-605 ◽  
Author(s):  
C. M. van der Aalst ◽  
K. A. M. van den Bergh ◽  
M. C. Willemsen ◽  
H. J. de Koning ◽  
R. J. van Klaveren
Keyword(s):  
Lung Cancer ◽  
Cancer Screening ◽  
Lung Cancer Screening ◽  
Smoking Abstinence ◽  
Cancer Screening Trial ◽  
Randomised Controlled ◽  
Screening Trial

Prognostic selection and long-term survival analysis to assess overdiagnosis risk in lung cancer screening randomized trials

2020 ◽  
pp. 096914132092303
Author(s):  
Eugenio Paci ◽  
Donella Puliti ◽  
Francesca Maria Carozzi ◽  
Laura Carrozzi ◽  
Fabio Falaschi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Screening ◽  
Survival Rates ◽  
Lung Cancer Screening ◽  
Term Survival ◽  
Long Term Survival ◽  
And Control ◽  
Screening Trial

Objectives Overdiagnosis in low-dose computed tomography randomized screening trials varies from 0 to 67%. The National Lung Screening Trial (extended follow-up) and ITALUNG (Italian Lung Cancer Screening Trial) have reported cumulative incidence estimates at long-term follow-up showing low or no overdiagnosis. The Danish Lung Cancer Screening Trial attributed the high overdiagnosis estimate to a likely selection for risk of the active arm. Here, we applied a method already used in benefit and overdiagnosis assessments to compute the long-term survival rates in the ITALUNG arms in order to confirm incidence-excess method assessment. Methods Subjects in the active arm were invited for four screening rounds, while controls were in usual care. Follow-up was extended to 11.3 years. Kaplan-Meyer 5- and 10-year survivals of “resected and early” (stage I or II and resected) and “unresected or late” (stage III or IV or not resected or unclassified) lung cancer cases were compared between arms. Results The updated ITALUNG control arm cumulative incidence rate was lower than in the active arm, but this was not statistically significant (RR: 0.89; 95% CI: 0.67–1.18). A compensatory drop of late cases was observed after baseline screening. The proportion of “resected and early” cases was 38% and 19%, in the active and control arms, respectively. The 10-year survival rates were 64% and 60% in the active and control arms, respectively ( p = 0.689). The five-year survival rates for “unresected or late” cases were 10% and 7% in the active and control arms, respectively ( p = 0.679). Conclusions This long-term survival analysis, by prognostic categories, concluded against the long-term risk of overdiagnosis and contributed to revealing how screening works.

Decreased cardiovascular mortality in the ITALUNG lung cancer screening trial: Analysis of underlying factors

Lung Cancer ◽  
2019 ◽  
Vol 138 ◽  
pp. 72-78 ◽  
Author(s):  
Donella Puliti ◽  
Mario Mascalchi ◽  
Francesca Maria Carozzi ◽  
Laura Carrozzi ◽  
Fabio Falaschi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Screening ◽  
Cardiovascular Mortality ◽  
Lung Cancer Screening ◽  
Trial Analysis ◽  
Cancer Screening Trial ◽  
Screening Trial
Sign in / Sign up

Export Citation Format

Share Document